T1	duration 393 399	5-year
T2	intervention 0 49	Risk-adapted targeted intraoperative radiotherapy
T3	control 57 82	whole-breast radiotherapy
T4	average-age 534 552	45 years and older
T5	outcome-Measure 1177 1240	absolute difference in local recurrence in the conserved breast
T6	outcome-Measure 1431 1458	complications and mortality
T7	duration 1584 1625	between March 24, 2000, and June 25, 2012
T8	intervention-participants 1627 1631	1721
T9	control-participants 1671 1675	1730
T10	No-of-participants 1827 1831	3451
T11	No-of-participants 1908 1912	2020
T12	No-of-participants 1929 1933	1222
T13	outcome 1950 1982	5-year risk for local recurrence
T14	intervention-value 2011 2015	3·3%
T15	control-value 2051 2055	1·3%
T16	outcome 2086 2121	TARGIT concurrently with lumpectomy
T17	intervention-value 2180 2184	2·1%
T18	control-value 2202 2206	1·1%
T19	outcome 2122 2136	(prepathology,
T20	outcome 2231 2260	delayed TARGIT (postpathology
T21	intervention-value 2315 2319	2·5%
T22	control-value 2351 2355	1·7%
T23	outcome 2386 2409	breast cancer mortality
T24	intervention-value 2444 2448	2·6%
T25	control-value 2473 2477	1·9%
T26	outcome 2541 2565	non-breast-cancer deaths
T27	intervention-value 2579 2583	1·4%
T28	control-value 2597 2601	3·5%
T29	outcome 2699 2716	Overall mortality
T30	intervention-value 2721 2725	3·9%
T31	control-value 2754 2758	5·3%
T32	outcome 2789 2816	Wound-related complications
T33	outcome 2855 2886	grade 3 or 4 skin complications
T34	intervention-value 2927 2931	four
T35	intervention-participants 2935 2939	1720
T36	control-value 2943 2945	13
T37	control-participants 2949 2953	1731
